Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Pemetrexed-induced acute kidney injury leading to chronic kidney disease.

Chauvet S, Courbebaisse M, Ronco P, Plaisier E.

Clin Nephrol. 2014 Dec;82(6):402-6. doi: 10.5414/CN107921.

PMID:
24424085
2.

Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.

Rombolà G, Vaira F, Trezzi M, Chiappini N, Falqui V, Londrino F.

J Nephrol. 2015 Apr;28(2):187-91. doi: 10.1007/s40620-014-0117-5. Epub 2014 Jul 2.

PMID:
24986522
3.

Renal damage induced by pemetrexed causing drug discontinuation: a case report and review of the literature.

Sbitti Y, Chahdi H, Slimani K, Debbagh A, Mokhlis A, Albouzidi A, Bennani F, Errihani H, Ichou M.

J Med Case Rep. 2017 Jul 28;11(1):182. doi: 10.1186/s13256-017-1348-6.

4.
5.

Acute tubular necrosis associated with mTOR inhibitor therapy: a real entity biopsy-proven.

Izzedine H, Escudier B, Rouvier P, Gueutin V, Varga A, Bahleda R, Soria JC.

Ann Oncol. 2013 Sep;24(9):2421-5. doi: 10.1093/annonc/mdt233. Epub 2013 Jun 24.

PMID:
23798615
6.

Pemetrexed-induced eyelid edema in lung cancer.

Martins-Filho PR, Kameo SY, Mascarenhas-Oliveira AC, Vieira NF, Azevedo E.

J Craniofac Surg. 2013 Jul;24(4):e401-3. doi: 10.1097/SCS.0b013e318285d5c2.

PMID:
23851735
7.

An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer.

Scagliotti GV, Felip E, Besse B, von Pawel J, Mellemgaard A, Reck M, Bosquee L, Chouaid C, Lianes-Barragán P, Paul EM, Ruiz-Soto R, Sigal E, Ottesen LH, Lechevalier T.

J Thorac Oncol. 2013 Dec;8(12):1529-37. doi: 10.1097/JTO.0000000000000005.

8.

Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer.

Gadgeel SM, Ruckdeschel JC, Patel BB, Wozniak A, Konski A, Valdivieso M, Hackstock D, Chen W, Belzer K, Burger AM, Marquette L, Turrisi A.

J Thorac Oncol. 2011 May;6(5):927-33. doi: 10.1097/JTO.0b013e3182156109.

10.

Phase II study of perioperative chemotherapy with cisplatin and pemetrexed in non-small-cell lung cancer.

Dy GK, Bogner PN, Tan W, Demmy TL, Farooq A, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Gannon J, Adjei AA, Adjei AA, Ramnath N.

J Thorac Oncol. 2014 Feb;9(2):222-30. doi: 10.1097/JTO.0000000000000062.

11.

Feasibility of home delivery of pemetrexed in patients with advanced non-squamous non-small cell lung cancer.

Lal R, Hillerdal GN, Shah RN, Crosse B, Thompson J, Nicolson M, Vikström A, Potter VA, Visseren-Grul C, Lorenzo M, D'yachkova Y, Bourayou N, Summers YJ.

Lung Cancer. 2015 Aug;89(2):154-60. doi: 10.1016/j.lungcan.2015.05.003. Epub 2015 May 12.

PMID:
26101013
12.

Predictive role of erythrocyte macrocytosis during treatment with pemetrexed in advanced non-small cell lung cancer patients.

Buti S, Bordi P, Tiseo M, Bria E, Sperduti I, Di Maio M, Panni S, Novello S, Rapetti SG, Pilotto S, Genestreti G, Rossi A, Pezzuolo D, Camisa R, Tortora G, Ardizzoni A.

Lung Cancer. 2015 Jun;88(3):319-24. doi: 10.1016/j.lungcan.2015.03.016. Epub 2015 Apr 1.

13.

Unusually prolonged pemetrexed cytotoxicity in a patient with a lung adenocarcinoma: a case report.

Sakhri L, Pinsolle J, Moro-Sibilot D, Pluchart H.

J Med Case Rep. 2017 Sep 16;11(1):262. doi: 10.1186/s13256-017-1436-7.

14.

Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.

Nicolson MC, Fennell DA, Ferry D, O'Byrne K, Shah R, Potter V, Skailes G, Upadhyay S, Taylor P, André V, Nguyen TS, Myrand SP, Visseren-Grul C, Das M, Kerr KM.

J Thorac Oncol. 2013 Jul;8(7):930-9. doi: 10.1097/JTO.0b013e318292c500.

15.

[Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer].

Hu X, Jiao S, Zhang S, Wang Z, Wang M, Huang C, Zheng R, Li K, Wang J, Wang Y, Ouyang X, Lv W, Cheng G, Hu C, Luo R, Sun Y.

Zhongguo Fei Ai Za Zhi. 2012 Oct;15(10):569-75. doi: 10.3779/j.issn.1009-3419.2012.10.02. Chinese.

16.

Pemetrexed-induced eyelid edema: incidence and clinical manifestations.

Schallier D, Decoster L, Fontaine C, De Grève J.

Anticancer Res. 2010 Dec;30(12):5185-8.

PMID:
21187510
17.

Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.

Gridelli C, Rossi A, Di Maio M, Leo S, Filipazzi V, Favaretto AG, Burgio MA, Cinieri S, Bianco R, Ciardiello F, Cavanna L, Bordonaro R, Costanzo R, Sandomenico C, Gallo C, Perrone F, Morabito A.

Clin Lung Cancer. 2014 Mar;15(2):166-70. doi: 10.1016/j.cllc.2013.11.011. Epub 2013 Nov 20.

PMID:
24418693
18.

A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.

Rodrigues-Pereira J, Kim JH, Magallanes M, Lee DH, Wang J, Ganju V, Martínez-Barrera L, Barraclough H, van Kooten M, Orlando M.

J Thorac Oncol. 2011 Nov;6(11):1907-14. doi: 10.1097/JTO.0b013e318226b5fa.

19.

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.

Paz-Ares L, Mezger J, Ciuleanu TE, Fischer JR, von Pawel J, Provencio M, Kazarnowicz A, Losonczy G, de Castro G Jr, Szczesna A, Crino L, Reck M, Ramlau R, Ulsperger E, Schumann C, Miziara JE, Lessa ÁE, Dediu M, Bálint B, Depenbrock H, Soldatenkova V, Kurek R, Hirsch FR, Thatcher N, Socinski MA; INSPIRE investigators.

Lancet Oncol. 2015 Mar;16(3):328-37. doi: 10.1016/S1470-2045(15)70046-X. Epub 2015 Feb 18.

PMID:
25701171

Supplemental Content

Support Center